Literature DB >> 6998551

Bone marrow transplantation in Canada.

N A Buskard.   

Abstract

Bone marrow transplantation is an established form of therapy for aplastic anemia and severe combined immunodeficiency. It is also a therapeutic option for acute leukemia in remission. Unfortunately, compatible donors are not available for most patients who could benefit from it. Further refinement of the techniques involved may make it suitable for more patients. Graft rejection, recurrent leukemia, graft-versus-host disease and interstitial pneumonia continue to be the main unsolved complications of bone marrow transplantation, but recent advances have decreased their frequency and severity. Most of the complications of allogeneic bone marrow transplantation may be eliminated with the use of autologous stem cells. For further refinement bone marrow transplantation should continue to be performed in large centres that combine treatment with research.

Entities:  

Mesh:

Year:  1980        PMID: 6998551      PMCID: PMC1704559     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  29 in total

1.  One-hundred-ten patients with aplastic anemia (AA) treated by marrow transplantation in Seattle.

Authors:  R Storb; E D Thomas; P L Weiden; C D Buckner; R A Clift; A Fefer; B W Goodell; F L Johnson; P E Neiman; J E Sanders; J Singer
Journal:  Transplant Proc       Date:  1978-03       Impact factor: 1.066

2.  Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor.

Authors:  R J O'Reilly; B Dupont; S Pahwa; E Grimes; E M Smithwick; R Pahwa; S Schwartz; J A Hansen; F P Siegal; M Sorell; A Svejgaard; C Jersild; M Thomsen; P Platz; P L'Esperance; R A Good
Journal:  N Engl J Med       Date:  1977-12-15       Impact factor: 91.245

3.  Chronic cutaneous graft-versus-host disease in man.

Authors:  H M Shulman; G E Sale; K G Lerner; E A Barker; P L Weiden; K Sullivan; B Gallucci; E D Thomas; R Storb
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

4.  Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions.

Authors:  B Speck; E Gluckman; H L Haak; J J van Rood
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

5.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

6.  ABO blood group system and bone marrow transplantation.

Authors:  R P Gale; S Feig; W Ho; P Falk; C Rippee; R Sparkes
Journal:  Blood       Date:  1977-08       Impact factor: 22.113

7.  ABO-incompatible bone marrow transplantation: preparation by plasma exchange and in vivo antibody absorption.

Authors:  E M Berkman; S Caplan; C S Kim
Journal:  Transfusion       Date:  1978 Jul-Aug       Impact factor: 3.157

8.  Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.

Authors:  F H Kung; W L Nythan; J Cuttner; G Falkson; P Lanzkowsky; V Del Duca; I U Nawabi; K Koch; H Pluess; A Freeman; E O Burgert; L A Leone; F Ruymann; R B Patterson; T Degnan; N Hakami; T F Pajak; J Holland
Journal:  Cancer       Date:  1978-02       Impact factor: 6.860

9.  Prolonged maintained remissions of adult acute non-lymphocytic leukaemia.

Authors:  B A Peterson; C D Bloomfield
Journal:  Lancet       Date:  1977-07-23       Impact factor: 79.321

10.  Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection.

Authors:  R Storb; R L Prentice; E D Thomas
Journal:  N Engl J Med       Date:  1977-01-13       Impact factor: 91.245

View more
  2 in total

1.  Bone marrow transplantation for leukemia and aplastic anemia: management of ABO incompatibility.

Authors:  J E Curtis; H A Messner
Journal:  Can Med Assoc J       Date:  1982-03-15       Impact factor: 8.262

Review 2.  Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials.

Authors:  Erika Kleiderman; Audrey Boily; Craig Hasilo; Bartha Maria Knoppers
Journal:  Stem Cell Res Ther       Date:  2018-11-08       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.